RESEARCH: CANCER
FOLDING PROJECT #16496 PROFILE

This project looks at RIPK2, a protein that's important in cancer. Researchers are using computer models to understand how special drugs called inhibitors work against RIPK2. By studying these models, they hope to learn how RIPK2 interacts with other proteins and how the inhibitors block this interaction. This knowledge could help develop better cancer treatments.

Note: This TLDR is a simplication and may not be 100% accurate.

Kinases are a major target for a variety of cancer therapies, but their mechanism of action is relatively unknown at a detailed atomic level, preventing us from understanding and optimizing known inhibitors.

One example is the Serine/Threonine Kinase RIPK2.

RIPK2 inhibition is useful for cancer targeting as it prevents RIPK2 from binding a protein partner named XIAP.

In fact, there are already 3 known inhibitors that bind to RIPK2 and prevent RIPK2-XIAP binding! However, it remains difficult to optimize these ligands for clinical purposes because we do not understand how any of these three inhibitors actually act on RIPK2 to prevent XIAP binding behavior.

These four projects are simulating RIPK2 by itself and bound to each of the three inhibitors, with the hope that this will reveal a more detailed mechanism of how each inhibitor works to prevent XIAP binding.

As a bonus, this will help reveal how RIPK2 *binds* XIAP (also unknown)! In this set of projects we are studying the following systems: 16466 – RIPK2 16467 – RIPK2:CSLP43 inhibitor-bound complex 16468 – RIPK2:CSLP48 inhibitor-bound complex 16469 – RIPK2:GSK583 inhibitor-bound complex 16470 – RIPK2:WEHI-345 inhibitor-bound complex 16471 – RIPK2:BI inhibitor-bound complex 16488 – RIPK2:BI inhibitor-bound complex (alt configuration) 16489 – RIPK2:BI inhibitor-bound complex (alt configuration 2) 16490 – RIPK2:NVS inhibitor-bound complex 16491 – RIPK2 apo from the GSK bound structure 16492 – RIPK2 apo fro the BI bound structure 16493 – RIPK2 apo from a Gefitinib bound structure 16494 – RIPK2 apo from a Novartis-produced inhibitor 16495 – RIPK2:Gefitinib complex 16496 – RIPK2:Novartis inhibitor structure.

---

Kinases

Enzymes that catalyze the transfer of phosphate groups

Kinases are a type of enzyme that play a crucial role in various cellular processes. They add phosphate groups to other molecules, which can activate or deactivate them. This process is essential for regulating cell growth, division, and death. Dysregulation of kinases is implicated in many diseases, particularly cancer.

---

RIPK2

Receptor-Interacting Protein Kinase 2

RIPK2 is a protein involved in the immune system's response to infection and inflammation. It plays a role in activating signaling pathways that lead to the production of inflammatory molecules. Mutations or dysregulation of RIPK2 can contribute to autoimmune diseases and cancer.

---

Inhibitors

Molecules that block or reduce the activity of a specific target

Inhibitors are substances that can prevent or slow down chemical reactions. In medicine, they are often used to treat diseases by blocking the activity of harmful proteins or enzymes. Cancer therapies frequently use inhibitors to target specific proteins involved in tumor growth.

---

XIAP

X-linked Inhibitor of Apoptosis Protein

XIAP is a protein that blocks programmed cell death (apoptosis). Cancer cells often overexpress XIAP to evade destruction. Inhibiting XIAP can make cancer cells more susceptible to apoptosis and may be a therapeutic strategy.

---

Ligands

Molecules that bind to a specific target (e.g., receptor, enzyme)

Ligands are molecules that can attach to other molecules, such as proteins or receptors. In drug development, ligands are often designed to specifically bind to targets involved in disease pathways, allowing for the treatment or modulation of those pathways.

---

CSLP43

Cancer Cell Survival Ligand 43

CSLP43 is a protein that interacts with RIPK2. Inhibitors targeting the interaction between RIPK2 and CSLP43 are being explored as potential cancer therapies.

---

GSK583

A specific inhibitor of RIPK2

GSK583 is a pharmaceutical compound that specifically inhibits the activity of RIPK2. It has shown promise as an anti-cancer agent in preclinical studies.

---

Gefitinib

A tyrosine kinase inhibitor

Gefitinib is a medication used to treat certain types of non-small cell lung cancer. It works by inhibiting the activity of specific enzymes involved in cancer cell growth.